The Evolution, Landscape, and Clinical Tradeoffs of In Vivo CAR-T Therapy
BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences · 22.07.2026
DOI: 10.70099/bj/2026.03.03.8 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences, online erschienen am 22.07.2026. Verfasst von Ming Ni. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized hematological oncology, yet conventional ex vivo manufacturing imposes severe clinical and economic burdens. In vivo CAR-T therapy—programming endogenous T cells via systemic vector delivery—has emerged to overcome these limitations. This communication analyzes the 2026 inflection point in in vivo CAR-T development, comparing lentiviral versus mRNA-LNP platforms. Early candidates (ESO-T01, LB2501) show promising efficacy and reduced toxicities, but urgent challenges persist: variable transduction efficiency, vector immunogenicity, off-target risks, and regulatory harmonization. Resolving these hurdles is imperative to translate this paradigm-shifting modality into standard clinical practice.
Zitieren
APA
Ni, M. (2026). The Evolution, Landscape, and Clinical Tradeoffs of In Vivo CAR-T Therapy. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. https://doi.org/10.70099/bj/2026.03.03.8
Vancouver
Ni M. The Evolution, Landscape, and Clinical Tradeoffs of In Vivo CAR-T Therapy. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. 2026. doi:10.70099/bj/2026.03.03.8
BibTeX
@article{Ni2026,
author = {Ni, Ming},
title = {The Evolution, Landscape, and Clinical Tradeoffs of In Vivo CAR-T Therapy},
journal = {BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences},
year = {2026},
doi = {10.70099/bj/2026.03.03.8}
}
EUVIMED